RAPT Therapeutics, Inc.
RAPTHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | $1.5M | $3.8M | $5.0M | — |
| Operating income | −$136.1M | −$127.1M | −$85.8M | −$69.2M | −$53.2M | −$43.6M |
| Net income | −$129.9M | −$116.8M | −$83.8M | −$69.2M | −$52.9M | −$43.0M |
| Total assets | $240.3M | $173.3M | $266.2M | $198.6M | $119.0M | $84.6M |
| Total liabilities | $50.4M | $26.3M | $21.0M | $12.3M | $14.8M | $11.5M |
| Equity | $189.9M | $147.0M | $245.2M | $186.4M | $104.2M | $73.1M |
| EPS (diluted) | $-3.19 | $-3.05 | $-2.58 | $-2.53 | — | — |
| Shares out. | 34.8M | 34.3M | 29.6M | 24.9M | 24.3M | 21.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- —
- Net margin
- —
- Return on equity
- −68.4%
- Return on assets
- −54.0%
- Return on capital (ROCE)
- −70.9%
- Liabilities / assets
- 21.0%
- Debt / equity
- 0.27×
- Book value / share
- $5.46
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -3.09distress
- Accruals / assets
- −19.4%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Feb 27, 2026 | 1.3M | 1.4 | -40.2% |
| Feb 13, 2026 | 2.2M | 1.0 | -30.5% |
| Jan 30, 2026 | 3.2M | 1.0 | +81.3% |
| Jan 15, 2026 | 1.8M | 6.4 | +7.6% |
| Dec 31, 2025 | 1.7M | 3.9 | +80.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMar 3, 2026
- Entered a material agreement · Regulation FD disclosureJan 20, 2026
- Regulation FD disclosureJan 14, 2026
- Director / officer changeNov 28, 2025
- Results of operationsNov 6, 2025
- Other material eventOct 23, 2025
- Regulation FD disclosure · Other material eventOct 20, 2025
- Results of operationsAug 7, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.